{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:39:26Z","timestamp":1785155966746,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.vaccine.2016.04.021","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T07:42:51Z","timestamp":1460706171000},"page":"2841-2846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990\u20132013"],"prefix":"10.1016","volume":"34","author":[{"given":"Elaine R.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe","family":"Bryant-Genevier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom T.","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.04.021_bib0150","unstructured":"PNEUMOVAX\u00ae 23 (pneumococcal vaccine polyvalent) package insert. Available at: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM257088.pdf [accessed 2.10.16]."},{"issue":"RR-11","key":"10.1016\/j.vaccine.2016.04.021_bib0155","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children \u2013 use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine \u2013 recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"34","key":"10.1016\/j.vaccine.2016.04.021_bib0160","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"40","key":"10.1016\/j.vaccine.2016.04.021_bib0165","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"25","key":"10.1016\/j.vaccine.2016.04.021_bib0170","first-page":"521","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6\u201318 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"37","key":"10.1016\/j.vaccine.2016.04.021_bib0175","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"34","key":"10.1016\/j.vaccine.2016.04.021_bib0180","doi-asserted-by":"crossref","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"64","author":"Kobayashi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.021_bib0185","first-page":"1","article-title":"General recommendations on immunization \u2013 recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Recomm Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2016.04.021_bib0190","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/01.inf.0000237830.33228.c3","article-title":"Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy","volume":"25","author":"Abzug","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.04.021_bib0195","series-title":"Vaccines","first-page":"542","article-title":"Pneumococcal polysaccharide vaccines","author":"Jackson","year":"2013"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.021_bib0200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/599824","article-title":"Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55\u201370 years of age","volume":"49","author":"Miernyk","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2016.04.021_bib0205","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.021_bib0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2016.04.021_bib0215","first-page":"52252","volume":"vol. 62","author":"Food and Drug Administration","year":"1997"},{"issue":"45","key":"10.1016\/j.vaccine.2016.04.021_bib0220","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009\u2013January 31, 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.021_bib0225","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"issue":"6","key":"10.1016\/j.vaccine.2016.04.021_bib0230","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.021_bib0235","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0264-410X(03)00521-8","article-title":"Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia","volume":"22","author":"T\u00f6rling","year":"2003","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2016.04.021_bib0240","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pds.1390","article-title":"Evaluating adverse events after vaccination in the Medicare population","volume":"16","author":"Burwen","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"25","key":"10.1016\/j.vaccine.2016.04.021_bib0245","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1016\/j.vaccine.2007.04.017","article-title":"Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults","volume":"25","author":"Cook","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.021_bib0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/hv.4.1.4747","article-title":"Evidence based route of administration of vaccines","volume":"4","author":"Cook","year":"2008","journal-title":"Hum Vaccin"},{"issue":"50","key":"10.1016\/j.vaccine.2016.04.021_bib0255","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1016\/j.vaccine.2008.08.052","article-title":"Vaccine injection technique and reactogenicity \u2013 evidence for practice","volume":"26","author":"Petousis-Harris","year":"2008","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2016.04.021_bib0260","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.vaccine.2009.01.125","article-title":"Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring","volume":"27","author":"Vellozzi","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.021_bib0265","series-title":"Pharmacoepidemiology","article-title":"Bias and confounding in pharmacoepidemiology","author":"Csizmadi","year":"2005"},{"issue":"30","key":"10.1016\/j.vaccine.2016.04.021_bib0270","doi-asserted-by":"crossref","first-page":"818","DOI":"10.15585\/mmwr.mm6430a3","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015\u201316 influenza season","volume":"64","author":"Grohskopf","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"10.1016\/j.vaccine.2016.04.021_bib0275","article-title":"Recommendations of the Immunization Practices Advisory Committee (ACIP) update: pneumococcal polysaccharide vaccine usage \u2013 United States","volume":"33","author":"Centers for Disease Control Prevention (CDC)","year":"1984","journal-title":"MMWR"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.021_bib0280","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.vaccine.2016.04.021_bib0285","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events","volume":"85","author":"Rosenthal","year":"1995","journal-title":"Am J Public Health"},{"issue":"6","key":"10.1016\/j.vaccine.2016.04.021_bib0290","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/cid\/civ423","article-title":"Deaths reported to the vaccine adverse event reporting system, United States, 1997\u20132013","volume":"61","author":"Moro","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T19:51:04Z","timestamp":1718481064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16301505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":29,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0264410X16301505"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990\u20132013","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}